Anti-Therapeutic Action: Amphotericin B nephrotoxicity

Fungal Infections – a Stealthy Enemy in Patients with Chronic Granulomatous Disease: a 28-years’ Experience from North India

mycolabadmin

Patients with chronic granulomatous disease (CGD), a rare immune system disorder, are highly susceptible to serious fungal infections. This study of 99 patients over 28 years found that 40% developed fungal infections, mostly caused by Aspergillus fungi affecting the lungs. These infections were life-threatening, with over half the infected patients dying despite aggressive treatment with antifungal medications. Doctors need to screen for fungal infections early, even in patients without obvious symptoms, and treat infants and males more aggressively.

Read More »

A case report of Saksenaea vasiformis mucormycosis infection of a lower segment caesarean section wound

mycolabadmin

A young woman developed a rare fungal infection (mucormycosis) in her caesarean section wound seven days after surgery. Despite initial antibiotic treatment, she required multiple surgical debridement procedures combined with antifungal medications to eliminate the infection. The surgical team successfully reconstructed her abdominal wall using specialized mesh and skin grafting techniques, resulting in complete healing.

Read More »

Epidemiology of mucormycosis in COVID-19 patients in northwest Iran: Rhizopus arrhizus as the predominant species

mycolabadmin

During the COVID-19 pandemic, some patients developed a severe fungal infection called mucormycosis alongside their coronavirus infection. This study found that 63 COVID-19 patients in Iran developed mucormycosis, which primarily affected the sinuses and brain. The researchers identified that a fungus called Rhizopus arrhizus caused most infections, and patients who received corticosteroids (used to treat severe COVID-19) had a higher risk, especially those who developed diabetes from the steroids.

Read More »
Scroll to Top